RARE vs SPRB
RARE: Ultragenyx is a biopharmaceutical company dedicated to transforming the lives of patients suffering from rare and ultra-rare genetic diseases through innovative therapeutic development. SPRB: A clinical-stage biopharmaceutical company advancing a breakthrough enzyme replacement therapy for the rare, neurodegenerative condition Sanfilippo Syndrome Type B.
Side-by-side fundamentals
| Metric | RARE | SPRB | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $15.29 | $45.54 | |
| Market cap | $1.5B | $131M | |
| Net margin FY2025, SEC XBRL | -85.4% | n/a | |
| Operating margin FY2025, SEC XBRL | -79.5% | n/a | |
| ROE FY2025, SEC XBRL | n/a | -91.7% | |
| ROA FY2025, SEC XBRL | -37.5% | -73.5% | RARE higher |
| Debt / equity as of 2026-09-02 | 90.54 | 0.19 | SPRB lower |
| Revenue growth (YoY) as of 2026-09-02 | +17.5% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +22.8% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 0.99 | 0.83 | |
| 1-year return as of 2026-10-08 close | -50.5% | -71.6% | RARE higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.